Innova Captab Ltd
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]
- Market Cap ₹ 4,866 Cr.
- Current Price ₹ 850
- High / Low ₹ 1,021 / 608
- Stock P/E 58.2
- Book Value ₹ 155
- Dividend Yield 0.24 %
- ROCE 10.8 %
- ROE 9.85 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 5.49 times its book value
- Company has a low return on equity of 11.5% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE 1000
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 373 | 411 | 785 | 859 | 865 | 958 | 1,299 | |
| 322 | 356 | 687 | 760 | 755 | 836 | 1,147 | |
| Operating Profit | 51 | 54 | 99 | 99 | 110 | 122 | 151 |
| OPM % | 14% | 13% | 13% | 11% | 13% | 13% | 12% |
| 1 | 1 | 3 | 9 | 9 | 17 | 13 | |
| Interest | 5 | 4 | 5 | 18 | 14 | 2 | 15 |
| Depreciation | 10 | 6 | 7 | 11 | 11 | 17 | 37 |
| Profit before tax | 38 | 46 | 89 | 78 | 94 | 120 | 112 |
| Tax % | 26% | 26% | 25% | 26% | 27% | 25% | 25% |
| 28 | 34 | 66 | 58 | 68 | 89 | 84 | |
| EPS in Rs | 232.42 | 287.50 | 551.50 | 11.99 | 11.91 | 15.63 | 14.62 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 15% |
| TTM: | 36% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 14% |
| TTM: | -7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -3% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 11% |
| Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 48 | 57 | 57 | 57 |
| Reserves | 98 | 133 | 199 | 220 | 666 | 756 | 829 |
| 54 | 45 | 176 | 237 | 244 | 329 | 321 | |
| 81 | 178 | 157 | 173 | 187 | 223 | 339 | |
| Total Liabilities | 245 | 368 | 544 | 678 | 1,155 | 1,365 | 1,547 |
| 73 | 79 | 161 | 161 | 164 | 637 | 648 | |
| CWIP | 0 | 7 | 0 | 22 | 339 | 21 | 15 |
| Investments | 0 | 0 | 60 | 60 | 60 | 60 | 101 |
| 172 | 282 | 322 | 435 | 593 | 647 | 782 | |
| Total Assets | 245 | 368 | 544 | 678 | 1,155 | 1,365 | 1,547 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 31 | 42 | 58 | 39 | 112 | 20 | 34 | |
| -6 | -20 | -188 | -88 | -472 | -100 | -14 | |
| -23 | -19 | 125 | 51 | 368 | 84 | -34 | |
| Net Cash Flow | 1 | 3 | -5 | 3 | 8 | 4 | -14 |
| Free Cash Flow | 27 | 23 | -21 | -39 | -165 | -141 | -28 |
| CFO/OP | 79% | 101% | 80% | 59% | 123% | 32% | 36% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 85 | 123 | 81 | 98 | 92 | 95 | 93 |
| Inventory Days | 84 | 107 | 63 | 67 | 68 | 94 | 80 |
| Days Payable | 92 | 132 | 84 | 102 | 111 | 119 | 112 |
| Cash Conversion Cycle | 77 | 99 | 60 | 63 | 49 | 70 | 60 |
| Working Capital Days | 45 | 39 | 23 | 44 | 58 | 65 | 94 |
| ROCE % | 28% | 33% | 21% | 15% | 12% | 11% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio (FATR) - Standalone Base x |
|
||||
| Installed Capacity - Capsules Million Units |
|||||
| Installed Capacity - Tablets Million Units |
|||||
| Net Working Capital Days Days |
|||||
| Actual Production - Capsules Million Units |
|||||
| Actual Production - Tablets Million Units |
|||||
| CDMO Customers Count Units |
|||||
| Export Presence (Count of Countries) Units |
|||||
| Number of CDMO Products Sold Units |
|||||
| Indian Formulation CDMO Market Share % |
|||||
| Pharmacy Touchpoints in India Units |
|||||
Extracted by Screener AI
Documents
Announcements
-
Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Change In Composition Of Committee Of The Board
26 May - Audit Committee reconstituted; Ms. Priyanka Dixit added effective 26 May 2026.
-
Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Change In Composition Of Audit Committee Of The Board
26 May - Audit Committee reconstituted with Ms. Priyanka Dixit added, effective 26 May 2025.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
25 May - Board reappointed auditors and directors on 25 May 2026; approved notice for 22nd AGM.
-
Announcement under Regulation 30 (LODR)-Change in Management
25 May - Board reappointed auditors and directors, and approved notice for 22nd AGM on 25 May 2026.
-
Board Meeting Outcome for Pursuant To Regulation 30, We Wish To Inform You That The Board Of The Company, At Its Meeting Held Today, I.E. On Monday, 25Th May, 2026, Inter-Alia Considered The Reappointment Of Auditors, Directors And Approval Of AGM Notice.
25 May - Board met on 25 May 2026; approved auditor and director reappointments and 22nd AGM notice.
Concalls
-
May 2026Transcript PPT REC
-
Feb 2026TranscriptPPT
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024Transcript PPT
Business Profile[1]
Innova Captab Limited is an integrated pharmaceutical player with a strong presence across the pharmaceutical value chain